Danish drugmaker Novo Nordisk has agreed to pay the United States and several states more than $1.7 million to resolve allegations that it caused false claims to be submitted to Medicare in connection with its diabetes drug, Novolin, according to a news release from the Federal Bureau of Investigation.
Novo Nordisk sales representatives in four states and the District of Columbia allegedly made payments to Rite Aid pharmacists in exchange for the pharmacists' recommendation of Novolin to patients. Through this, pharmacists allegedly allowed Novo Nordisk representatives to access confidential patient information for marketing purposes. The representatives allegedly used this information to design marketing events intended to switch patients from competitor diabetes drugs to Novolin.
"The allegations in this case were particularly egregious because they involved the disclosure of confidential patient information," U.S. Attorney Loretta E. Lynch said in the release.
Read the release on Novo Nordisk's settlement.
Related Articles on Pharmaceutical Fraud:
Johnson & Johnson to Pay South Carolina $327M for Deceptive Drug Marketing
Michigan Accuses McKesson of Inflating Drug Prices, Overbilling Medicaid
UCB Pleads Guilty to Off-Label Marketing of Epilepsy Drug; Will Pay $34M
Novo Nordisk sales representatives in four states and the District of Columbia allegedly made payments to Rite Aid pharmacists in exchange for the pharmacists' recommendation of Novolin to patients. Through this, pharmacists allegedly allowed Novo Nordisk representatives to access confidential patient information for marketing purposes. The representatives allegedly used this information to design marketing events intended to switch patients from competitor diabetes drugs to Novolin.
"The allegations in this case were particularly egregious because they involved the disclosure of confidential patient information," U.S. Attorney Loretta E. Lynch said in the release.
Read the release on Novo Nordisk's settlement.
Related Articles on Pharmaceutical Fraud:
Johnson & Johnson to Pay South Carolina $327M for Deceptive Drug Marketing
Michigan Accuses McKesson of Inflating Drug Prices, Overbilling Medicaid
UCB Pleads Guilty to Off-Label Marketing of Epilepsy Drug; Will Pay $34M